Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of tenofovir-associated bone adverse outcomes among a US National Historical Cohort of HIV-infected veterans

Trial Profile

Study of tenofovir-associated bone adverse outcomes among a US National Historical Cohort of HIV-infected veterans

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jul 2018

At a glance

  • Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Atazanavir/ritonavir; Darunavir/ritonavir; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Lopinavir/ritonavir; Rilpivirine; Ritonavir
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Jul 2018 New trial record
    • 01 Jun 2018 Results published in the Infectious Diseases and Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top